Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTLA0VS)

• DTT Name: Complement factor P (CFP)
• Synonyms: Properdin; CFP
• Gene Name: CFP
• DTT Type: Clinical trial target; [1]
• UniProt ID: PROP_HUMAN
• TTD ID: T08029
• Sequence:
  MITEGAQAPRLLLPPLLLLLTLPATGSDPVLCFTQYEESSGKCKGLLGGGVSVEDCCLNT
  AFAYQKRSGGLCQPCRSPRWSLWSTWAPCSVTCSEGSQLRYRRCVGWNGQCSGKVAPGTL
  EWQLQACEDQQCCPEMGGWSGWGPWEPCSVTCSKGTRTRRRACNHPAPKCGGHCPGQAQE
  SEACDTQQVCPTHGAWATWGPWTPCSASCHGGPHEPKETRSRKCSAPEPSQKPPGKPCPG
  LAYEQRRCTGLPPCPVAGGWGPWGPVSPCPVTCGLGQTMEQRTCNHPVPQHGGPFCAGDA
  TRTHICNTAVPCPVDGEWDSWGEWSPCIRRNMKSISCQEIPGQQSRGRTCRGRKFDGHRC
  AGQQQDIRHCYSIQHCPLKGSWSEWSTWGLCMPPCGPNPTRARQRLCTPLLPKYPPTVSM
  VEGQGEKNVTFWGRPLPRCEELQGQKLVVEEKRPCLHVPACKDPEEEEL
• Function: A positive regulator of the alternate pathway of complement. It binds to and stabilizes the C3- and C5-convertase enzyme complexes.
• KEGG Pathway: Herpes simplex virus 1 infection (hsa05168)
• Reactome Pathway:
  Activation of C3 and C5 (R-HSA-174577)
  Defective B3GALTL causes PpS (R-HSA-5083635)
  O-glycosylation of TSR domain-containing proteins (R-HSA-5173214)
  Neutrophil degranulation (R-HSA-6798695)
  Regulation of Complement cascade (R-HSA-977606)
  Alternative complement activation (R-HSA-173736)

Molecular Interaction Atlas (MIA) of This DTT

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALXN1820	DMNZOJ3	Sickle-cell disorder	3A51	Phase 2	[2]
CLG561	DMU6R3O	Geographic retinal atrophy	9B78.9	Phase 2	[3]

References

• [1] Properdin in complement activation and tissue injury. Mol Immunol. 2013 Dec 15;56(3):191-8.
• [2] Clinical pipeline report, company report or official report of Alexion
• [3] Complement inhibition as a therapeutic strategy in retinal disorders. Expert Opin Biol Ther. 2019 Apr;19(4):335-342.